WEBULL
WebtradeDownload

How Investors May Respond To Spyre Therapeutics Stock After Phase 2 Data And Wider Losses

Simply Wall St · 1d ago
  • Spyre Therapeutics reported a third quarter 2026 net loss of US$96.12 million, or US$0.94 per share, alongside positive Phase 2 data for SPY003 in inflammatory bowel disease and progress on its broader autoimmune pipeline.
  • The combination of heavier reported losses and funding for an expanded hidradenitis suppurativa program highlights how Spyre Therapeutics is leaning hard into costly late stage trial preparation while still pre revenue.
  • We will now examine how Spyre Therapeutics' investment narrative is affected by deeper third quarter losses alongside encouraging SPY003 Phase 2 data.

Compare Spyre Therapeutics' high burn and late stage ambitions with a curated set of autoimmune and biotech peers, screened for balance sheet strength and funding runway inside the list of solid balance sheet and fundamentals (25 results).

Spyre Therapeutics Investment Narrative Recap

To own Spyre Therapeutics, you need to believe its multi asset autoimmune pipeline can translate positive mid stage data into approvable therapies before the cash runway tightens. The latest quarter shows that this is an expensive plan. Net loss widened to US$96.12 million, or US$0.94 per share, which keeps execution risk firmly in focus.

The short term story still revolves around completing key Phase 2 programs in inflammatory bowel disease and hidradenitis suppurativa on time and without major safety or efficacy surprises. The biggest risk is that heavier spending continues while licensing limits, mixed SPY072 data and any trial stumbles slow the path to later stage studies.

The most relevant fresh update is the combination of Spyre Therapeutics’ larger third quarter loss and the decision to fund a broader hidradenitis suppurativa push on the back of positive topline SPY003 and TL1A data. That pairing shows management leaning into higher trial spend at the same time as reported losses expand.

For you, the link to catalysts is clear. The new SKYLIGHT Phase 2 hidradenitis study and the proof of concept readout for SPY003 in inflammatory bowel disease sit alongside existing SKYLINE and SKYWAY plans. Progress or delays across these programs, against a backdrop of licensing constraints and ongoing cash use, is likely to shape how investors reassess execution risk and runway comfort over the next few years.

Spyre Therapeutics' narrative projects US$28.9 million revenue and US$5.0 million earnings by 2029. This implies revenue growth from a zero base and an earnings improvement of about US$155.2 million from earnings today of a US$150.2 million loss.

Uncover why Spyre Therapeutics' fair value indicates a 21% potential upside to its current price that may not last much longer.

NasdaqGS:SYRE 1-Year Stock Price Chart
NasdaqGS:SYRE 1-Year Stock Price Chart

Exploring Other Perspectives

Fair value estimates for Spyre Therapeutics from the Simply Wall St Community cluster tightly between US$120.08 and US$122.53 across 2 separate models, so you are seeing aligned optimism rather than a wide scatter. Those views pre date the much heavier recent losses and SPY003 data, which gives you clear reasons to explore alternative opinions before acting.

Explore another Spyre Therapeutics fair value estimate, including one that suggests it could be worth just $120.08!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

Looking For More Investment Ideas Beyond Spyre Therapeutics?

Spyre Therapeutics might be your current focus, yet your overall portfolio benefits when you line it up against other opportunities with different risk and return profiles. A targeted screener can help you quickly sort through the market and find companies that better match your preferred balance of quality, valuation, income, and stability.

  • For investors who want potential mispricing combined with solid fundamentals, scan for companies flagged as 34 high quality undervalued stocks. These may offer a more attractive entry point than the headline tickers everyone is watching.
  • If resilience and balance sheet strength matter most to you, filter the universe using our 31 resilient stocks with low risk scores and focus on businesses where financial risk sits lower on the list of concerns.
  • Income focused investors can put cash to work in a targeted way by reviewing the 5 dividend fortresses and concentrating on companies that pair higher yields with an emphasis on stability.